GlassScriptPhysician profile
Ali S Alshati
NPI 1538692926
$28,413.12
in general payments reported to CMS, 2019-2025
18 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.52 · 2023: $1,800 · 2024: $25K · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $25K · Food and Beverage: $2,271 · Travel and Lodging: $1,036 · Education: $93.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $25,000.00 |
| Food and Beverage | $2,271.04 |
| Travel and Lodging | $1,035.57 |
| Education | $93.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26,755.32 | 2022-2025 | Apollo Esg System, Exalt Model D, Obsidio |
| Janssen Biotech, INC. | $428.64 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $203.81 | 2024-2025 | Entyvio |
| Abbvie INC. | $193.76 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $144.78 | 2023-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.31 | 2024-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $67.51 | 2025 | Iqirvo |
| Genzyme Corporation | $56.00 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $54.65 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $50.94 | 2025 | Ibsrela |
| Lilly USA, LLC | $45.87 | 2024-2025 | Omvoh |
| Csl Behring | $33.27 | 2025 | Kcentra |
| Aimmune Therapeutics, INC. | $32.46 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $24.52 | 2024 | Vegzelma |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $20.97 | 2024 | Suflave, Sutab |
| Gilead Sciences, INC. | $20.45 | 2025 | |
| Evoke Pharma, INC. | $16.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Alshati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.